Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 billion pie.
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate